No biologic | Anti-IgE | Anti-IL5 or anti-IL5R | |
All patients n | 242 | 129 (omalizumab: n=129) | 305 (benralizumab: n=98, mepolizumab: n=182, reslizumab: n=25) |
PCR test for COVID-19 | |||
Not done | 211 | 118 | 281 |
Positive | 3 (1.2%) | 0 | 6 (2%) |
Negative | 28 | 11 | 18 |
IgG test for COVID-19 | |||
Not done | 241 | 99 | 238 |
Positive | 0 | 4 (3.1%) | 4 (1.3%) |
Negative | 1 | 26 | 63 |
Daily OCS n | 20 (8.2%) | 10 (7.8%) | 28 (9.2%) |
Median dose mg (prednisone equivalent) | 4.5 | 5.0 | 5.0 |
Confirmed COVID-19 patients n | 3 | 4 | 7 |
% of subgroup | 1.2# | 3.1# | 2.3# |
Hospitalisation n | 1 | 0 | 4 |
Duration of hospitalisation days | 5 | NA | 4.5 (range 2–8) |
O2 therapy n | 1 | 0 | 2 |
Duration of O2 therapy days | 3 | NA | 5.5 (range 3–8) |
NA: not applicable; OCS: oral corticosteroid. #: Chi-square test, p>0.05.